Aeluma (ALMU) Q4 2026 earnings review
Balance sheet secured, but core manufacturing model shifts
Aeluma reported Q4 revenue of $0.6 million, down 55.8% against a year ago, beating the $521,000 implied by the full-year guide. The company raised $20.1 million via its at-the-market program, pushing total cash to $56.0 million, and signed a $30 million letter of intent with the CHIPS R&D Office. Operating loss widened to $4.4 million as R&D expenses multiplied.
⚖️ Verdict: ⚪ Neutral
The case is where it was — a neutral verdict — because securing the balance sheet only buys time for the core commercialization problem. The cash infusion removes the near-term dilution risk that hung over the prior quarter, but management's decision to procure internal manufacturing tools weakens the capital-light narrative.
What the print did not settle is when Aeluma will transition from government projects to commercial AI datacom revenue. The progression of current non-recurring engineering negotiations into a qualified supply agreement provides the first real reading.
🐂 Bull Case
Selling Shares to Remove the Capital Overhang
Aeluma issued 830,484 shares through its at-the-market program at an average price of $24.87, raising $20.1 million and bringing total cash to $56 million. The raise eliminates the immediate capital uncertainty that hung over the prior quarter. With the business burning roughly $1.8 million in free cash this quarter, the balance sheet now provides significant runway to execute the datacom roadmap without forcing another dilutive event before commercial traction arrives.
Advancing Toward Datacom Monetization
The bottleneck in the existing Indium Phosphide supply chain remains the core driver for Aeluma's alternative platform. This quarter, management confirmed the company advanced to multi-million-dollar non-recurring engineering negotiations for AI datacom applications. Securing an NRE agreement would mark the first formal financial commitment from a hyperscaler or prime supplier, validating the architecture ahead of a final production decision.
🐻 Bear Case
Adding Capital Intensity to a Fab-Light Model
Management historically pitched a capital-light scaling strategy anchored by partnerships with Tower Semiconductor and Sumitomo Chemical to avoid the heavy fixed costs of building a traditional foundry. This quarter's print cuts against that framing: the company is explicitly procuring its own specialized semiconductor manufacturing equipment (MOCVD tools) to increase internal wafer production capacity.
The pivot toward internal capacity carries immediate margin consequences. R&D expenses jumped to 390.7% of revenue — a 378-point expansion year-over-year — driving operating margins down to negative 751%. The number to watch is next year's capital expenditure line as these tools are delivered, which will verify how far the company is straying from a pure fabless model.
Still Pre-Commercial After the AI Cycle's First Wave
While the company is negotiating engineering agreements, it has not yet signed a definitive commercial supply deal. Revenue of $0.6 million for the quarter fell 55.8% year-over-year and remains entirely tied to lumpy government research contracts. The prolonged timeline confirms that Aeluma is still in the evaluation phase, meaning it will likely miss the initial waves of optical component procurement driving today's AI datacenter build-outs.
Standing risks the print did not read on
Two standing risks regarding commercial timing received no update in this release; each requires explicit customer disclosures to evaluate.
- Mobile SWIR sensor adoption: no timeline given for a shift from technical evaluation to pricing and delivery.
- Customer qualification: no update on when any of the 30-plus active engagements will reach a binding production decision.
👓 Other Themes
The $30M CHIPS Act LOI
Aeluma signed a letter of intent for up to $30 million with the Department of Commerce CHIPS R&D Office. As non-dilutive government funding, it provides a secondary mechanism to offset the new MOCVD tool investments, though the funding remains subject to definitive negotiations and binding milestones.
💲 Other KPIs
Grew 17.6% year-over-year, driven by the issuance of 830,484 shares through the ATM program to secure the balance sheet.
Down 15.2 points from 40.8% a year ago, reflecting the uneven profitability of early-stage government research contracts compared to the prior period's mix.
🔮 Guidance
Management issued no numerical guidance for FY27, confirming the year will be spent on technology development, team growth, and engineering negotiations rather than scaled product revenue.
❓ Key Questions
The Cost of Internal Capacity
What is the expected capital expenditure required for the new MOCVD tools, and how does owning capacity alter the target operating margins compared to the original fab-light model?
NRE Timeline
Assuming a successful non-recurring engineering phase for AI datacom, how many quarters typically separate the completion of that engineering work from recognizing the first dollar of commercial product revenue?
CHIPS Funding Milestones
What specific operational or commercial milestones are tied to unlocking the $30 million in CHIPS funding, and how much of that total is designated for facility expansion versus research?